We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technologies Fuel EU Diagnostics Market

By HospiMedica staff writers
Posted on 04 Oct 2005
Sparked by new technologies and other medical advances, the European in vitro diagnostics (IVD) market is expected to reach U.S.$43 billion in 2011, up from $28.7 billion in 2004, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm.

The expanding aged population and molecular diagnostics will also help boost the IVD market, although cost containment and changing economic conditions worldwide are hindering the uptake of IVD technologies. More...
This is particularly true in developing nations in Asia, Latin America, and Africa, where poor healthcare infrastructures and struggling economies impede modernization and create environments that are extremely price sensitive. Distribution, local suppliers, and minimal expenditures for healthcare also create hurdles to market growth.

Recently, healthcare awareness programs and government initiatives to increase spending have stimulated improvements in European countries, creating opportunities for future growth. As markets become more competitive and consumers raise demands, low prices, multiple tests on a single platform, and customer service gain importance. Understanding specific markets and clinical needs is increasingly important to promote adoption of new technologies, according to Silvia Cerqueira, an analyst with Frost & Sullivan. "New IVD systems must also address unmet needs and provide substantial added value.” Smaller companies can combat regulatory challenges by collaborating with larger companies and benefiting from their experience and economic resources.

Discoveries and innovations in molecular diagnostics are propelling the advancement of personalized medicine and creating new growth opportunities for IVDs. As manufacturers concentrate on providing greater benefits such as early diagnosis, improved decision-making, and better monitoring of treatment, the market will maintain its strong growth trajectory. Rising insurance coverage in such countries as France, Spain, and Germany will also contribute to positive trends in the market.




Related Links:
Frost & Sullivan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.